Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%
In patients with advanced NSCLC with PD-L1 ≥50%, first-line cemiplimab monotherapy improved survival and patient-reported outcomes over chemotherapy for those who received prior radiotherapy for symptomatic brain metastases.
Authors
- Mahmut Gümüş (ORCID: https://orcid.org/0000-0003-3550-9993)
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- Frank Seebach
- Mustafa Özgüroğlu (ORCID: https://orcid.org/0000-0002-8417-8628)
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Saadettin Kılıçkap (ORCID: https://orcid.org/0000-0003-1637-7390)
- J-F. Pouliot
- Dmitry Bentsion
- Jennifer McGinniss
- İrfan Çiçin (ORCID: https://orcid.org/0000-0002-7584-3868)
- Oleg Gladkov
- Virote Sriuranpong (ORCID: https://orcid.org/0000-0001-8787-5026)
- Hacı Mehmet Türk (ORCID: https://orcid.org/0000-0003-2206-8148)
- Petra Rietschel
- Ruben G.W. Quek (ORCID: https://orcid.org/0000-0001-9602-3239)
- Ahmet Sezer (ORCID: https://orcid.org/0009-0005-0183-5573)
- Giuseppe Gullo (ORCID: https://orcid.org/0000-0001-5325-1055)
- Xuanyao He
- D. McIntyre
Institutions
- Chulalongkorn University (TH)
- Regeneron (United States) (US)
- Başkent University (TR)
- King Chulalongkorn Memorial Hospital (TH)
- Bezmiâlem Vakıf Üniversitesi (TR)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- Ulyanovsk Regional Oncology Center (RU)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- Cancer
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1002/cncr.35864
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Sanofi
- Regeneron Pharmaceuticals